Cigna

Landmark Settlement: The Cigna Group Resolves FTC Insulin Pricing Suit, Reshaping the PBM Landscape

In a move that marks a definitive shift in the American pharmaceutical supply chain, The Cigna Group (NYSE: CI) has reached a comprehensive settlement with the Federal Trade Commission (FTC) to resolve a contentious lawsuit regarding the pricing of insulin. Announced in early February 2026, the agreement effectively ends years

Healthcare

The Great Unbundling: How Federal Scrutiny is Dismantling the PBM Profit Machine

The long-standing dominance of Pharmacy Benefit Managers (PBMs) in the American healthcare system has reached a critical inflection point as 2025 draws to a close. For decades, these "middlemen" operated in the shadows, negotiating drug prices and rebates with manufacturers while managing prescription benefits for millions. However, a